Follow LF0 researchXLinkedInSubstackFacebookTelegramDiscord

Weekly Performance Update — November 20, 2026

Across 255 articles, our hit rate is 83.7% and our average signal return is 23.3%, so the overall record is still strong this run. Among the tiers with meaningful sample sizes, Sell is performing best on both accuracy and average signal return, while

Executive Summary

Across 255 articles, our hit rate is 83.7% and our average signal return is 23.3%, so the overall record is still strong this run. Among the tiers with meaningful sample sizes, Sell is performing best on both accuracy and average signal return, while Buy is the weakest tier by a wide margin; Hold remains mixed rather than decisive.

This is one in a recurring series that reviews LF0 Research’s own past ratings against what actually happened to the stock. The goal is an honest scorecard, not a highlight reel — full methodology and every call we’ve ever made is at /research-performance/.

If You’d Followed Every Pick

Beyond individual calls, here’s the model portfolio question: what if you’d put $1 into every Buy/Strong Buy pick the day we published it, and a separate $1 short into every Sell/Strong Sell pick? We’ve rated stocks at very different times — some calls go back to June 2026, others were made last week — so each pick’s $1 only joins its book on its own publish date. The return below is pooled value versus total capital actually deployed at each point in time, not a return measured from one shared start date.

  • Long book: -10.2% on 6 pick(s), $1 each. $6.00 deployed is worth $5.39 today.
  • Short book: +25.8% on 80 pick(s), $1 each. $80.00 deployed is worth $100.61 today.
  • Combined, long + short (i.e. every pick since we started): +23.3% on 86 pick(s), $1 each. $86.00 deployed is worth $106.00 today.

For comparison, here’s what the same $86.00 would have returned in a lump-sum buy-and-hold of the broad market since our first tracked pick (2026-06-09). This isn’t an identical methodology, since our capital went in gradually rather than all at once, but it’s the closest honest same-period reference point:

  • S&P 500 (SPY): -2.4%. $86.00 would be worth $83.95 today.
  • Nasdaq-100 (QQQ): -8.7%. $86.00 would be worth $78.54 today.

This Week’s Calls

CUE — Sell (Notable mover — best active signal return)

What we said: We argued that Cue Biopharma’s clinical optionality was outrunning its cash generation, with only $27.1M of cash at year-end 2025 and a runway into Q1 2027. We also pointed to the rich 5.1x EV/revenue valuation and the risk that burn near $50.1M TTM would force dilution before the science proved itself.

What happened: The stock fell from 26.96 to 4.50, a return of -83.3%.

Why: That bearish setup held up: the financing clock mattered more than the patent base, and the shares moved sharply lower before the clinical proof we wanted to see. The original concern about limited cash and heavy burn was the right one to focus on.

Read the original article

BW — Sell (Notable mover — best active signal return)

What happened: The stock fell from 17.76 to 4.19, a return of -76.4%.

Why: Our Sell call was directionally right because the equity never escaped the debt and cash-flow overhang we highlighted. The move shows that the recovery case still had not translated into the kind of operating improvement needed to support the stock.

Read the original article

RCAT — Sell (Notable mover — best active signal return)

What happened: The stock fell from 7.83 to 1.94, a return of -75.2%.

Why: The Sell thesis held up because the defense moat did not yet turn into durable economics. The weak operating, net, and free-cash-flow margins we cited remained the more important issue than the strategic story.

Read the original article

NLST — Sell (Notable mover — worst active signal return)

What we said: We said the stock was pricing in cleaner cash conversion than Netlist had actually delivered, even after Q1 2026 revenue reached $104.9M and EBITDA turned positive at $8.6M. The key risk we named was still -$15.5M of operating cash flow TTM, which meant the improvement had not yet shown up in self-funding economics.

What happened: The stock rose from 2.44 to 4.18, a return of 71.3%.

Why: This call has been wrong so far because the market rewarded the revenue and EBITDA step-up more than we expected. Our caution about cash conversion was valid, but it has not been enough to offset the rerating that followed the stronger reported numbers.

Read the original article

SDGR — Sell (Notable mover — worst active signal return)

What we said: We argued that Schrödinger’s platform moat was real, but that the business was still consuming capital, with operating cash flow at -$126.9M TTM and valuation at 3.9x EV/revenue. We said we would only improve the rating if free cash flow turned positive and revenue growth re-accelerated.

What happened: The stock rose from 17.40 to 26.34, a return of 51.4%.

Why: That bearish stance has not held up so far because the market was willing to look past the cash burn and pay for the platform. The specific cash-flow concern we emphasized was real, but it was not enough to keep the shares down.

Read the original article

SM — Buy (Notable mover — worst active signal return)

What we said: We rated SM a Buy because free cash flow was already covering the merger and debt load, with $1.5B of TTM free cash flow and a 15.5% FCF yield. We also said the valuation at 5.1x EV/EBITDA looked too low if the South Texas sale and deleveraging played out as expected.

What happened: The stock fell from 40.38 to 29.34, a return of -27.3%.

Why: This was the wrong call because the expected deleveraging and integration benefits did not support the shares in the way we expected. The cash-flow strength we cited was not enough to overcome the market’s concern about the merger and balance-sheet path.

Read the original article

How Each Rating Did

Buy — 6 call(s)

  • Average signal return: -10.2%, accuracy +16.7%
  • Helped most: CAR (+5.5%)
  • Hurt most: SM (-27.3%)

This tier is weak this run: with 6 calls, accuracy is only 16.7% and the average signal return is negative. SM was the biggest drag, while CAR was the best of a small group, but the sample is still too small to treat that as a durable pattern.

Hold — 169 call(s)

  • Average move: -5.9%, accuracy +56.2%
  • Held steadiest: COHU (+0.0%)
  • Moved the most: EOSE (-81.5%)

Hold has been mixed rather than cleanly right or wrong, with 169 calls and 56.2% accuracy. COHU was the steadiest name, while EOSE moved the most, which is a reminder that this tier often captures cases where the thesis is more about waiting than making a strong directional bet.

Sell — 57 call(s)

  • Average signal return: +28.1%, accuracy +86.0%
  • Helped most: CUE (+83.3%)
  • Hurt most: NLST (-71.3%)

Sell is the strongest tier this run, with 57 calls, 85.0% accuracy, and a positive average signal return. CUE was the best performer for the tier, while NLST was the main miss, but the overall record still shows that our bearish calls have generally been working.

Strong Sell — 23 call(s)

  • Average signal return: +19.9%, accuracy +95.7%
  • Helped most: SMR (+56.8%)
  • Hurt most: SHIP (-0.0%)

Strong Sell is also performing very well, with 23 calls and 95.7% accuracy, though we should still remember that smaller samples can flatter a tier. SMR was the standout winner, while SHIP was the weakest name in the group.

Sector Tilt

How the calls we’re actively tracking are distributed across sectors:

SectorLongShortHoldTotal
Technology0243357
Industrials1162542
Healthcare2102032
Consumer Cyclical041721
Consumer Defensive011819
Energy151319
Basic Materials231318
Financial Services051015
Communication Services05611
Utilities0369
Real Estate0246
Unclassified0235

Cumulative Signal Return

Lessons This Week

The clearest pattern this week is that our bearish calls worked best when we anchored on a specific financing or cash-conversion problem that the market could not ignore, as with CUE and BW. The misses came when we leaned too hard on cash-burn skepticism while the market instead rewarded a visible step-up in reported revenue or EBITDA, as with NLST and SDGR. That is a useful reminder to keep separating “good story, weak cash flow” from “weak story, but the market is already repricing the improvement.”

Conclusion

Putting it all together: a $1 long book of every Buy/Strong Buy pick is at $0.90 (-10.2%) across 6 picks; and a $1 short book of every Sell/Strong Sell pick is at $1.26 (+25.8%) across 80 picks.

So far, the short book has outpaced the long book.

This is a running scorecard, not a finished one — both books will keep changing as more picks join and more tracking windows close. We’ll keep restating this comparison every week.

"Want

"Sign

Educational content only, not investment advice. Hypothetical results, not a guarantee of future performance.

Past performance does not guarantee future results. Nothing here is investment advice or a recommendation to buy or sell securities. Ratings are tracked for 182 days from publication, then frozen as a permanent record.

Research disclaimer

This material is provided for research and educational purposes only. It is not investment advice, a recommendation, or an offer to buy or sell any security or strategy.

Leave a Comment

Your email address will not be published. Required fields are marked *